Table 2 Microbiological tests and antifungal treatments in all patients.

From: Implications for the diagnosis of aspiration and aspergillosis in critically ill patients with detection of galactomannan in broncho-alveolar lavage fluids

N = 69

ASP

(n = 39)

pIPA

(n = 30)

p

SOFA first GM positivity†

11 (7, 13)

13 (10, 15)

0.02

BALF-positive GM

 First value of GM (BALF) †

2.0 (1.25, 4.32)

4.50 (2.28, 5.74)

< 0.01

 Highest value of GM (BALF) †

2.7 (1.4, 4.9)

5.8 (4.5, 7.3)

< 0.001

Aspergillus spp. culture positive

1 (2.6%)

14 (47%)

< 0.001

Antifungal therapy

 Antifungal prophylaxis

2 (5.1%)

7 (23%)

0.04

 First-line therapy [yes]

15 (38%)

27 (90%)

< 0.001

 Second-line therapy [yes]

3 (7.7%)

15 (50%)

< 0.001

  1. Data are presented as n (%).
  2. †Values are presented as median, (Interquartile range).
  3. SOFA (Sequential organ failure assessment), GM (Galactomannan), BALF (Broncho-alveolar lavage fluid).
Back to article page